Ipilimumab treats lung adenocarcinoma?

The U.S. Food and Drug Administration (FDA) has approved Ipilimumab (Ipilimumab) combined with nivolumab (Nivolumab) as first-line treatment for the treatment of metastatic non-small cell lung cancer expressing PD-L1 (≥1) without EGFR or ALK genomic tumor abnormalities;AlsoCombined with nivolumab and2 cycles of platinum doublet chemotherapy, first-line treatment of metastatic or recurrent non-small cell lung cancer without EGFR or ALK genomic tumor abnormalities This is a monoclonal antibody that can effectively block cytotoxic T cell antigen-4 (CTLA-4) molecules and activate the immune system to recognize and kill tumor cells. It is mainly used to treat advanced melanoma and is administered intravenously.